ALNY Stock Price Today (October 2026) — Alnylam Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-07
Alnylam Pharmaceuticals, Inc. (ALNY) is trading at $224.41, up 0.21% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $371.12 (65.4% upside).
- Volatility is moderate (37.72% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (66.90% YoY) alongside competitive pressures in the Biotechnology space.
ALNY Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Alnylam Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $29.71B
P/E Ratio
Forward P/E: 19.12
Revenue Growth
Year over Year
Analyst Target
+65.4% upside potential
Key Investor Questions About ALNY
What investors need to know before buying
Based on current market data, ALNY presents a neutral technical setup with mixed signals fundamentals.
- Technicals say: Neutral (RSI 35.21)
- Fundamentals say: Mixed signals (nuanced financial profile)
ALNY's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for ALNY investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.99B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, ALNY stock traded between $197.81 and $495.55 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 37.72% annualized volatility and β=0.44, the stock exhibits low sensitivity to market moves—making ALNY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and discussing changes in the market that prompted a revision to its 2026 TTR franchise revenue outlook.
Alnylam’s Zilebesiran Targets Twice-Yearly Blood Pressure Control in ZENITH Trial
Alnylam Pharmaceuticals (NASDAQ:ALNY) outlined its strategy for advancing zilebesiran, an investigational RNA interference, or RNAi, therapy designed to provide sustained blood-pressure control with twice-yearly dosing for people with uncontrolled hypertension and elevated cardiovascular risk. Duri
Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?
Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture
Analysts think Alnylam could rebound strongly over the next 12 months.
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects
ALNY, BMRN, RARE and BBIO offer rare-disease growth potential through strong products, pipeline catalysts and high unmet medical needs.
Alnylam's Latest Data Strengthen Outlook for Nucresiran, TRITON-CM, Oppenheimer Says
Alnylam Pharmaceuticals' (ALNY) latest data strengthen the case for Nucresiran and TRITON-CM success
Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself
Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 29, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) is currently trading at $224.41. The RSI (14-day) is at 35.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $371.12 implies 65.4% upside from current levels. Volatility is moderate at 37.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Alnylam Pharmaceuticals, Inc. (ALNY): The trailing P/E ratio is 42.95, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 19.12, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.45, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 24.69. Price-to-Sales is 6.96. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering ALNY, the consensus price target is $371.12. This represents a 65.4% upside from the current price of $224.41. The range spans from a low target of $256.00 to a high target of $536.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Alnylam Pharmaceuticals, Inc. (ALNY) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Alnylam Pharmaceuticals, Inc. (ALNY) investors include: 1. Moderate volatility (37.7% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 2.21x) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Alnylam Pharmaceuticals, Inc.'s (ALNY) current debt and financial health profile: Total debt stands at $2.99B. The debt-to-equity ratio is 2.21x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 3.06, indicating strong short-term liquidity. The quick ratio is 2.79. The company holds $3.31B in cash and equivalents. Free cash flow is positive at $271.54M, providing a cushion for debt servicing and shareholder returns.